Melphalan, ASCT Consolidation Remains Preferred Option in Transplant-eligible Multiple Myeloma

Share this content:
Consolidation with melphalan and autologous stem-cell transplantation (ASCT) remains the preferred option in transplant-eligible multiple myeloma.
Consolidation with melphalan and autologous stem-cell transplantation (ASCT) remains the preferred option in transplant-eligible multiple myeloma.

Consolidation with high-dose melphalan and autologous stem-cell transplantation (ASCT) remains the preferred option in transplant-eligible patients with multiple myeloma, even though chemotherapy plus lenalidomide has a better safety profile, a new study published online ahead of print in the journal The Lancet Oncology has shown.1

Currently, high-dose melphalan plus ASCT is the standard treatment strategy in transplant-eligible patients with newly diagnosed multiple myeloma.

For the open-label, multicenter, phase 3 study, researchers enrolled 389 transplant-eligible patients with newly diagnosed multiple myeloma 65 years or younger. All patients received induction with 4 28-day cycles of lenalidomide, dexamethasone, and cyclophosphamide, followed by granulocyte colony-stimulating factor (GCSF) for stem-cell mobilization and collection.

Of the 389 participants, 256 were eligible for consolidation. Patients were randomly assigned to receive 6 cycles of cyclophosphamide 300 mg/m2 on days 1, 8, and 15, dexamethasone 40 mg on days 1, 8, 15, and 22, and lenalidomide 25 mg on days 1-21, or 2 courses of high-dose melphalan 200 mg/m2 plus ASCT.

There were also 223 patients eligible for maintenance therapy. Those patients were randomly assigned to receive maintenance lenalidomide 10 mg on days 1-21 plus prednisone 50 mg every other day or lenalidomide alone.

Results showed that median progression-free survival during consolidation was 28.6 months (95% CI, 20.6 - 36.7) with chemotherapy plus lenalidomide and 43.3 months (95% CI, 33.2 - 52.2) with high-dose melphalan and ASCT (HR for the first 24 months, 2.51; 95% CI, 1.60 - 3.94; P < .0001). Researchers found no significant difference in progression-free survival between maintenance groups (HR, 0.84; 95% CI, 0.59 - 1.20; P = .34).

In regard to safety, there were fewer grade 3 or 4 adverse events reported in the chemotherapy plus lenalidomide treatment arm than in the melphalan plus ASCT arm.

Reference

  1. Gay G, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial [published online ahead of print on November 16, 2015]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00389-7.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters